{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:25:01Z","timestamp":1784870701454,"version":"3.55.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":836,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:00:00Z","timestamp":1695513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Thure F and Karin Forsberg's Foundation","award":["2020-03"],"award-info":[{"award-number":["2020-03"]}]},{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["7017-00131B"],"award-info":[{"award-number":["7017-00131B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sveland Foundation"},{"name":"University of Copenhagen Foundation for Scientific Studies in Companion Animals","award":["2020-0002"],"award-info":[{"award-number":["2020-0002"]}]},{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["7017\u201000131B"],"award-info":[{"award-number":["7017\u201000131B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A variant in the canine phosphodiesterase (PDE) 5A gene (PDE5A:E90K) is associated with decreased concentrations of circulating cyclic guanosine monophosphate (cGMP) and response to PDE5 inhibitor treatment. Pimobendan is a PDE inhibitor recommended for medical treatment of certain stages of myxomatous mitral valve disease (MMVD) in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>PDE5A:E90K polymorphism attenuates the inhibitory effect of pimobendan on in vitro platelet aggregation and increases basal platelet aggregation in Cavalier King Charles Spaniels (CKCS). Selected clinical variables (MMVD severity, sex, age, hematocrit, platelet count in platelet-rich plasma [PRP], and echocardiographic left ventricular fractional shortening [LV FS]) will not show an association with results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fifty-two privately owned CKCS with no or preclinical MMVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using blood samples, we prospectively assessed PDE5A genotype using Sanger sequencing and adenosine diphosphate-induced platelet aggregation response (area under the curve [AUC], maximal aggregation [MaxA], and velocity [Vel]) with and without pimobendan using light transmission aggregometry. Dogs also underwent echocardiography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pimobendan inhibited platelet function as measured by AUC, MaxA, and Vel at a concentration of 10\u2009\u03bcM (P\u2009&amp;lt;\u2009.0001) and Vel at 0.03\u2009\u03bcM (P\u2009&amp;lt;\u2009.001). PDE5A:E90K polymorphism did not influence the inhibitory effect of pimobendan or basal platelet aggregation response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>The PDE5A:E90K polymorphism did not influence in vitro basal platelet aggregation response or the inhibitory effect of pimobendan on platelet aggregation in CKCS. Dogs with the PDE5A:E90K polymorphism did not appear to have altered platelet function or response to pimobendan treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16871","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T02:54:16Z","timestamp":1695610456000},"page":"2145-2156","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["No impact of polymorphism in the phosphodiesterase 5A gene in Cavalier King Charles Spaniels on pimobendan-induced inhibition of platelet aggregation response"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7824-3323","authenticated-orcid":false,"given":"Maria J.","family":"Reimann","sequence":"first","affiliation":[{"name":"University of Copenhagen Department of Veterinary and Animal Sciences, , Frederiksberg,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Faisst","sequence":"additional","affiliation":[{"name":"University of Copenhagen Department of Veterinary and Animal Sciences, , Frederiksberg,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Knold","sequence":"additional","affiliation":[{"name":"University of Copenhagen Department of Veterinary and Animal Sciences, , Frederiksberg,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Meurs","sequence":"additional","affiliation":[{"name":"North Carolina State University Department of Clinical Sciences, , Raleigh, North Carolina,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Stern","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of California-Davis Department of Medicine and Epidemiology, , Davis, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe E.","family":"Cremer","sequence":"additional","affiliation":[{"name":"University of Copenhagen Department of Veterinary Clinical Sciences, , Frederiksberg,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E.","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital Rigshospitalet Department of Cardiology, , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6617-0454","authenticated-orcid":false,"given":"Ingrid","family":"Ljungvall","sequence":"additional","affiliation":[{"name":"Swedish University of Agricultural Sciences Department of Clinical Sciences, , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-023X","authenticated-orcid":false,"given":"Jens","family":"H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[{"name":"Swedish University of Agricultural Sciences Department of Clinical Sciences, , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0292-3111","authenticated-orcid":false,"given":"Lisbeth H.","family":"Olsen","sequence":"additional","affiliation":[{"name":"University of Copenhagen Department of Veterinary and Animal Sciences, , Frederiksberg,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"issue":"6","key":"2026021401270855700_jvim16871-bib-0001","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1034\/j.1399-0004.1999.560401.x","article-title":"Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?","volume":"56","author":"Nebert","year":"1999","journal-title":"Clin Genet"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0002","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0003","first-page":"485","article-title":"Human blood platelet 3\u2032:5\u2032-cyclic nucleotide phosphodiesterase. Isolation of low-km and high-km phosphodiesterase","volume":"429","author":"Hidaka","year":"1976","journal-title":"BBA Enzymol"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4103\/2045-8932.87303","article-title":"Pulmonary hemodynamic responses to inhaled NO in chronic heart failure depend on PDE5 G(\u22121142)T polymorphism","volume":"1","author":"Damy","year":"2011","journal-title":"Pulm Circ"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jvim.12256","article-title":"Identification of PDE5A:E90K: a polymorphism in the canine phosphodiesterase 5A gene affecting basal cGMP concentrations of healthy dogs","volume":"28","author":"Stern","year":"2014","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0006","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1038\/s41598-019-43318-z","article-title":"Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension","volume":"9","author":"Ueda","year":"2019","journal-title":"Sci Rep"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0007","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1939-1676.2006.tb01803.x","article-title":"Heart disease as a cause of death in insured Swedish dogs younger than 10\u2009years of age","volume":"20","author":"Egenvall","year":"2006","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0008","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"Keene","year":"2019","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1939-1676.2001.tb02313.x","article-title":"Increased platelet aggregation response in Cavalier King Charles Spaniels with mitral valve prolapse","volume":"15","author":"Olsen","year":"2001","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0010","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1939-1676.2008.0150.x","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study","volume":"22","author":"H\u00e4ggstr\u00f6m","year":"2008","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0011","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5326\/0420249","article-title":"Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs","volume":"42","author":"Lombard","year":"2006","journal-title":"J Am Anim Hosp Assoc"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0012","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2460\/ajvr.74.3.403","article-title":"In vitro effect of pimobendan on platelet aggregation in dogs","volume":"74","author":"Shipley","year":"2013","journal-title":"Am J Vet Res"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0013","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors\u2014pharmacology and clinical applications 20\u2009years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2026021401270855700_jvim16871-bib-0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111128","article-title":"Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors","volume":"134","author":"Ahmed","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0015","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.bcp.2003.12.028","article-title":"Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3","volume":"67","author":"Feijge","year":"2004","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-291X(87)90728-5","article-title":"Direct evidence for the modulation of human platelet cytosolic free Ca2+ by intracellular cyclic AMP produced with a photoactivatable derivative","volume":"146","author":"Blache","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0017","first-page":"333","article-title":"Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells","volume":"56","author":"Eldor","year":"1986","journal-title":"Thromb Haemost"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0018","first-page":"1389","article-title":"Use of the novel cardiotonic and vasodilator agent pimobendan in traumatic shock","volume":"38","author":"Bitterman","year":"1988","journal-title":"Arzneimittel-Forschung\/Drug Res"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0019","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/cvr\/23.3.184","article-title":"Platelet aggregation inhibitory effects of the new positive inotropic agents pimobendan and UD CG 212 in whole blood","volume":"23","author":"Saniabadi","year":"1989","journal-title":"Cardiovasc Res"},{"key":"2026021401270855700_jvim16871-bib-0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0049-3848(86)91635-X","article-title":"UDCG 115 a benzimidazo-pyridazinone compound with cardiovascular activity inhibits platelet thrombus formation","volume":"41","author":"Bastida","year":"1986","journal-title":"Thromb Res"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0021","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMsa063904","article-title":"Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development","volume":"355","author":"Murad","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0022","first-page":"549","article-title":"Chronic valvular disease in the Cavalier King Charles Spaniel in Sweden","volume":"131","author":"H\u00e4ggstr\u00f6m","year":"1992","journal-title":"Vet Rec"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1939-1676.2007.0008.x","article-title":"Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease","volume":"22","author":"Borgarelli","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026021401270855700_jvim16871-bib-0024","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fvets.2020.00423","article-title":"Pharmacokinetics of Pimobendan and its metabolite O-Desmethyl-Pimobendan following rectal administration to healthy dogs","volume":"7","author":"Her","year":"2020","journal-title":"Front Vet Sci"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1939-1676.2002.tb02350.x","article-title":"Idiopathic asymptomatic thrombocytopenia in Cavalier King Charles Spaniels is an autosomal recessive trait","volume":"16","author":"Pedersen","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026021401270855700_jvim16871-bib-0026","first-page":"29","article-title":"Canine and Feline Cardiology","author":"Gompf","year":"1988"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0027","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1111\/jvim.15331","article-title":"ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats","volume":"32","author":"Acierno","year":"2018","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0028","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1748-5827.1994.tb03921.x","article-title":"Thrombocytopenia in the Cavalier King Charles Spaniel","volume":"35","author":"Eksell","year":"1994","journal-title":"J Small Anim Pract"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0029","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jth.12231","article-title":"Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC\/ISTH","volume":"11","author":"Cattaneo","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.tvjl.2014.01.001","article-title":"R-R interval variations influence the degree of mitral regurgitation in dogs with myxomatous mitral valve disease","volume":"199","author":"Reimann","year":"2014","journal-title":"Vet J"},{"key":"2026021401270855700_jvim16871-bib-0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2020.105457","article-title":"Intermittent mitral regurgitation in Cavalier King Charles Spaniels: short-term progression and influence of stress tests","volume":"258","author":"Reimann","year":"2020","journal-title":"Vet J"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0032","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/jvim.14586","article-title":"Effect of Pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study-a randomized clinical trial","volume":"30","author":"Boswood","year":"2016","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0033","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/jvim.14759","article-title":"Mitral regurgitation severity and left ventricular systolic dimension predict survival in young Cavalier King Charles Spaniels","volume":"31","author":"Reimann","year":"2017","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0034","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.tvjl.2010.07.019","article-title":"Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs","volume":"189","author":"Moesgaard","year":"2011","journal-title":"Vet J"},{"key":"2026021401270855700_jvim16871-bib-0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fvets.2020.00267","article-title":"Assessment of P2Y12 inhibition by clopidogrel in feline platelets using flow cytometry quantification of vasodilator-stimulated phosphoprotein phosphorylation","volume":"7","author":"Li","year":"2020","journal-title":"Front Vet Sci"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0036","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/vcp.12795","article-title":"Hemostatic function in Cavalier King Charles Spaniels assessed using thromboelastography","volume":"48","author":"\u00d6berg","year":"2019","journal-title":"Vet Clin Pathol"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0037","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1939-1676.2003.tb02500.x","article-title":"Decreased platelet function in Cavalier King Charles Spaniels with mitral valve regurgitation","volume":"17","author":"Tarnow","year":"2003","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0038","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1939-1676.2005.tb02720.x","article-title":"Dogs with heart diseases causing turbulent high-velocity blood flow have changes in platelet function and von Willebrand factor multimer distribution","volume":"19","author":"Tarnow","year":"2005","journal-title":"J Vet Intern Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0039","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/vr.135.12.281","article-title":"Macrothrombocytosis in Cavalier King Charles Spaniels","volume":"135","author":"Brown","year":"1994","journal-title":"Vet Rec"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/ani10020201","article-title":"Platelet function and therapeutic applications in dogs: current status and future prospects","volume":"10","author":"Cortese","year":"2020","journal-title":"Animals"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0041","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/ijms18081803","article-title":"Platelet aggregometry testing: molecular mechanisms, techniques and clinical implications","volume":"18","author":"Koltai","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0042","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12199-017-0687-7","article-title":"Effects of methanol and formic acid on human platelet aggregation","volume":"22","author":"Marumo","year":"2017","journal-title":"Environ Health Prev Med"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0043","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/09537100400020161","article-title":"Can platelet aggregometry be standardized?","volume":"16","author":"Breddin","year":"2005","journal-title":"Platelets"},{"key":"2026021401270855700_jvim16871-bib-0044","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.vascn.2015.02.002","article-title":"The evaluation of drug-induced changes in cardiac inotropy in dogs: results from a HESI-sponsored consortium","volume":"75","author":"Guth","year":"2015","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0045","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jvp.12235","article-title":"The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs","volume":"39","author":"Bell","year":"2016","journal-title":"J Vet Pharmacol Ther"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0046","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jvp.12243","article-title":"Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs","volume":"39","author":"Yata","year":"2016","journal-title":"J Vet Pharmacol Ther"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0047","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00005344-199103000-00003","article-title":"Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium","volume":"17","author":"Endoh","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"2026021401270855700_jvim16871-bib-0048","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1939-165X.2007.tb00222.x","article-title":"Platelet function in dogs: breed differences and effect of acetylsalicylic acid administration","volume":"36","author":"Nielsen","year":"2007","journal-title":"Vet Clin Pathol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/6\/2145\/66895656\/jvim16871.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/6\/2145\/66895656\/jvim16871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:27:18Z","timestamp":1771050438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/37\/6\/2145\/8483287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16871","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"2023-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}